Elevance Health Inc (ELV · NYSE)

ELV · MARKET VIEW

Market view · as of Jul 6, 2026

Revenue (TTM)
$200.42B
+2.6% YoY
Gross margin
25.9%
EPS (latest q)
$12.58
vs $10.81 est · beat
52-wk position
96.9%
-1.1% vs 52w high · +7.3% 1mo

Price (last ~year)

Elevance Health (ELV) recently lowered its full-year earnings guidance due to projected increases in medical costs, despite reporting $50.18 billion in revenue for the quarter ending March 31, 2026. The company, which maintains a $90.75 billion market capitalization, recorded a 2.6% year-over-year revenue increase against a 16.8% decline in earnings. Shares are currently trading at $417.89, approaching the $421.43 analyst target following a 34.6% gain over the past three months.

Valuation

Market cap
$90.75B
P/E
17.7
PEG
1.53
P/B
2.067
P/S
0.453
Beta
0.683
Analyst target
$421.43

Quality & returns

Gross margin
25.9%
Operating margin
5.3%
Profit margin
2.6%
ROE
12.1%
ROA
4.0%

Price movement

Last
$417.89
1-month
+7.3%
3-month
+34.6%
RSI (14)
61
vs SMA200
+22.2%
52-wk position
96.9% -1.1% vs high

Quarterly trajectory

Revenue by quarter (oldest → newest)

QuarterRevenueOp incomeNet incomeEBITDA
2026-03-31$50.18B$2.66B$1.76B$2.77B
2025-12-31$49.75B$581.0M$547.0M$987.0M
2025-09-30$50.71B$1.76B$1.19B$2.14B
2025-06-30$49.78B$2.63B$1.74B$3.01B

Recent news

Sources this view read

  • fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
  • filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
  • earnings Reported earnings history (Alpha Vantage EARNINGS)
  • prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)

Other snapshots